- Home
- / PrimeCell Advanced Therapy
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
PrimeCell Advanced Therapy financials data including stock price, CreditSafe score, income statement, and balance sheet.
Revenue
KČ23.5 M
FY, 2018
CreditSafe Score
?
Score changed on Jun 07, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| CZK | FY, 2017 | FY, 2018 |
|---|---|---|
| Revenue | 26.3M | 23.5M |
| Revenue growth, % | -10.5% | |
| Cost of goods sold | 18.8M | 14.8M |
| Gross profit | 7.4M | 8.7M |
| Gross profit margin, % | 28.3% | 37.2% |
| General and administrative expense | 11.6M | 10.9M |
| Operating expense total | 19.6M | 18.7M |
| EBIT | (7.7M) | 13.7M |
| EBIT margin, % | -29.3% | 58.3% |
| Interest income | 1.5M | 2.6M |
| Interest expense | 563.0K | 2.3M |
| Pre tax profit | (6.8M) | 12.4M |
| Net Income | (6.8M) | 12.4M |